

#### **PUBLIC WEBINAR**

# Artificial Intelligence (AI) in Quality Measurement

Brian Anderson, MITRE

Jeffrey Geppert, Battelle

## Agenda

Topics we'll cover include:

- Overview of the Coalition for Health AI (CHAI)
- A Nationwide Network of Health AI Assurance Laboratories
- Al Assurance in the Development and Evaluation of Clinical Quality Measures



## Who We Are


- Over 1300+ Private Sector Organizations: Health systems, payors, device manufacturers, technology companies, patient advocates
- US Govt Partners: HHS, FDA, ONC NIH, CMS, White House OSTP, AHRQ, VA, NIST, CDC, OCR
- Formally became 501c6 non-profit in Jan 2024






## **Core Principles for Responsible Health Al**

4



## **CMS National Quality Strategy Goals**


#### **CMS National Quality Strategy Goals**





2/20/2024

# Foundational Models for Medicine – an Approach to Quality Improvement



**Regulations:** Application approval; validation; audits; community-based challenges; analyses of biases, fairness and diversity **Acronyms:** Electronic health records (EHRs), Generalist medical artificial intelligence (GMAI)



6

2/20/2024


# Bridging the Gap between Risk Prediction & Quality Improvement

- Model Development for Outcome Risk Prediction & Stratification
  - CMS AI Outcome Challenge
    - Bias Mitigation
    - Transparency
    - Explainability & Interpretability
- Tying Quality Improvement Metrics to Clinical Outcomes
- Weighting & Instructional Tuning for Equity
- Causal Machine Learning & "Patients Like This"



## **Reducing Burden – the power of LLMs**

 Rethinking digital Quality Measures (dQMs) and Measurement Calculation Tools (MCTs)



**Acronyms:** Electronic health records (EHRs), Fast Healthcare Interoperability Resources (FHIR)

MITRE

## **Generative AI and Summarization:** Automating Measurement Capture from Conversation to Orders

Lindsey Spellman, MD			-	
To Review Note Archive	«	Add content to this section	Copy All	>> Beta Coding Transcript
Pamela Placeholder DOB: 09.09.1995		Review of Systems Constitutional: - Confirms fatigue Cardiovascular:		All right, well, Shahji, you're my patient and, um, I heard you're having some shortness of breath.
Oct. 10, 2023 05:46 PM 0:57 Donna Demo DOB: 05.05.2010		<ul> <li>Confirms swelling in legs</li> <li>Denies chest pain or pressure</li> <li>Respiratory: <ul> <li>Confirms waking up at night with shortness of breath</li> <li>Neurologic:</li> <li>Denies lightheadedness</li> </ul> </li> <li>Assessment &amp; Plan</li> <li>Congestive Heart Failure (CHF): Patient reports worsening shortness of breath, leg swelling, and nocturnal dyspnea over the past week.</li> </ul>	Tell me what's going on. Oh, yeah. I have a lot of <b>shortness of breath</b>	
Oct. 10, 2023 06:16 PM 3:01 Rachel Record DOB: 10.10.1940			veek.	When I walk up the stairs or when I walk on flat ground, I get swelling in my legs. Oh, my goodness.
Oct. 10, 2023 06:56 PM 1:21 Patricia Participant 00B: 07.07.1975		<ul> <li>Schedule an office visit for a physical exam, EKG, and echocardiogram.</li> <li>R peat blood work including BMP and CBC.</li> <li>Discuss the importance of weight monitoring and dietary changes with a dietician.</li> <li>Chronic Kidney Disease (CKD): Patient was advised to stop Lasix due to</li> </ul>		Sometimes I wake up at night short of breath, too, so.
Oct. 10, 2023 07:09 PM 1:35 ohn Doe		concerns about kidney function.       Yeah.         - Monitor kidney function closely and adjust medications as necessary.       Yeah.         Uncontrolled Diabetes: Patient's diabetes is not well-controlled, contributing to their overall health issues.       How long has this been going or Like 3 months.         - Initiate insulin therapy and provide education on insulin administration.       Like 3 months.         - Schedule a nurse visit to discuss insulin management.       Wow.	How long has this been going on for?	
Oct. 19, 2023 01:26 PM 0:04 John Doe				
Oct. 19, 2023 01:41 PM 0:06		How was the quality of the generated note?	ជ ជ ជ ជ ជ	And has it been about the same?.
Y Prev Page Next Page      Select	ct All	▶ 0:00 ●	1	3:01 1x Complete & Send



## Al Assurance in the Development and Evaluation of Clinical Quality Measures

## Al Assurance in the Development of CQM



#### An analogy with Patient Reported Outcome Measures-Performance Measures (PRO-PMs)

PRO-PMs use a Patient Reported Outcome Measure (PROM) in the construction of a measure


There are separate processes and criteria for evaluating the feasibility, reliability, and validity of the PROM separate from the PRO-PM



#### An analogy with electronic Clinical Quality Measures (eCQMs)

eCQMs use specific standards for data elements and logic (e.g. Fast Healthcare Interoperability Resources)


There are separate feasibility, reliability, and validity considerations for eCQMs in addition to standard considerations that apply to all CQM



Clinical Quality Measures (CQMs) that use Artificial Intelligence (AI) in some way



## A Potential AI "Model Card" for CQM




## A Potential AI "Model Card" for CQM Cont.

Rule-Based					
Parsing Strategy	Rule Evaluation Order	Fallback Mechanisms			
Dependencies & Resources	Coverage & Limitations	Adaptability & Extension			
Dictionaries & Lexicons Grammar Frameworks	Coverage Known Gaps	Customizability Integration Points			
History & Evolution	Collaborators & Contributors	Validation & Testing			

History & Evolution	Collaborators & Contributors	Validation & Testing
Rule Revision History		Test Suites
Rationale		Performance Metrics
	2/20/2024	Traceability

## A Potential AI "Model Card" for CQM Cont. 2



## Al Assurance in the Evaluation of CQM

Criteria/Assertions	Question	External Validity to Quality Program Population
Meaningfulness	Degree of uncertainty in how, why, for whom, and under what conditions a measure yields net benefit	
Feasibility		Does the explicit articulation of the people, processes, and technology required for data collection and reporting extrapolate to the quality program population? Do most entities in the quality program population have access to those people, processes, and technology
Appropriateness of scale		How are benefits and harms distributed across identifiable subpopulations of either persons or entities?
Time to value realization	Degree of uncertainty in how, why, for whom, and under what conditions a measure's net benefit and/or net net benefit will change over time	How might benefits and harms change over time?

Al Assurance in the Evaluation of CQM – Appropriateness of Scale – Lessons from Environmental Justice



## Inequality

Refers to a difference in access across populations

Inequalities have many potential drivers and do not necessarily indicate a need for policy intervention (e.g., related to personal choice, cultural factors, disposable income)



## Inequity

Refers to a difference that persists even after controlling for these drivers/factors


Specifically, there may be lower access in underserved or underresourced communities (e.g., rural communities, lower-income households)



## Injustice

Refers to cases where policies or other persistent or systematic factors exacerbate, or perpetuate, existing inequities

# Al Assurance in the Evaluation of CQM – Appropriateness of Scale – Lessons from Environmental Justice Cont.





## **Questions?**



Battelle <u>MMSSupport@battelle.org</u> CMS Melissa Gross <u>melissa.gross@cms.hhs.gov</u>

Angela Wright angela.wright@cms.hhs.gov

Gequincia Polk gequincia.polk@cms.hhs.gov